How to Avoid Desk Rejection at Frontiers in Immunology

The biggest misconception about Frontiers in Immunology is that broad publication volume means loose editorial standards.

Authors submit papers thinking it's an easy backup option after Nature Immunology or Immunity rejections. This triggers desk rejection more often than weak science does.

Frontiers editors aren't screening for revolutionary novelty. They're screening for fit with collaborative review and clinical relevance. Papers get desk rejected when the clinical context is absent, the specialty section choice is obviously wrong, or the methodology doesn't meet systematic standards. Have you considered how your basic research connects to disease mechanisms?

Poor clinical context kills basic research submissions. Frontiers wants to publish basic immunology, but editors expect authors to frame findings with translational implications that could guide future therapeutic development or disease understanding. A paper on T cell receptor signaling that doesn't mention potential therapeutic applications or disease relevance won't survive editorial screening, even if the experimental design is solid.

Wrong specialty section submissions are instant rejections. Authors often submit to "Immunology" thinking it's the general category when it actually focuses on fundamental mechanisms. Each of the 19 sections has specific scopes and editorial teams that don't transfer papers between sections. A cancer immunotherapy paper submitted to "Vaccines and Molecular Therapeutics" instead of "Cancer Immunity and Immunotherapy" gets bounced immediately.

Systematic review methodology failures trigger automatic desk rejection. Frontiers publishes many systematic reviews and meta-analyses, but PRISMA compliance isn't optional. Papers that skip systematic search strategies, don't report screening processes, or lack proper evidence synthesis methodology get rejected before peer review begins.

Open science requirements aren't suggestions. Frontiers requires detailed data availability statements, and editors verify whether authors can actually provide the data they're claiming to share. Papers that dodge open science requirements or provide vague data availability language get flagged for desk rejection.

The collaborative review model means editors need papers that can benefit from constructive peer feedback and iterative improvement. Manuscripts that are too preliminary for useful review input or too poorly framed for the right section often get filtered out early.

Submit to the wrong section? You're done.

Frontiers in Immunology's specialty sections operate as distinct editorial units with their own scopes and handling teams. Authors commonly default to the broadest-sounding section and assume it will function as a catch-all category. That is often the wrong move. If your paper has disease models, therapeutic implications, or a specific translational lane, it usually needs the section that actually reflects that context.

Clinical and translational sections want clear patient or disease relevance. Cancer-focused sections want obvious oncology context. Vaccine and therapeutic sections want intervention logic rather than only descriptive immunology.

Authors frequently submit cancer vaccine papers to Clinical Immunology when they belong in Vaccines and Molecular Therapeutics. This creates immediate editorial conflicts that lead to desk rejection.

Why don't editors always transfer papers between sections? Because section teams have specialized expertise and review networks. If the paper arrives mismatched, the fastest decision is often still rejection rather than rescue-routing.

Every submission needs clinical context. Period.

Your mouse study doesn't need human data, but it needs clear connections to human disease and therapeutic potential. What specific pathways could your findings target? Which diseases could benefit from this research direction? These connections must appear throughout your manuscript, not just in throwaway discussion sentences.

Disease context strengthens basic research submissions tremendously. A dendritic cell activation study gains editorial interest when authors connect findings to vaccine development, autoimmune mechanisms, or cancer immunotherapy approaches. The experimental methodology can be identical, but clinical framing determines editorial reception and reviewer assignment.

Editors distinguish between authentic clinical thinking and retroactive justification attempts. Integration throughout introduction and discussion sections improves editorial reception substantially. Can you explain why clinicians should care about your findings? If not, revise before submitting.

Frontiers publishes substantial systematic reviews but maintains strict methodology requirements. Poor systematic approach equals fast rejection.

PRISMA compliance means complete checklists and selection flowcharts, not partial compliance. Editors expect systematic database searches with documented search strings, clear database selection rationale, and transparent inclusion criteria that other researchers could replicate. Reviews reporting "we searched PubMed and Google Scholar" without specific search terms don't meet editorial standards.

Search strategy documentation must be reproducible. Include exact search strings, database interfaces used, search date ranges, and screening procedures with inter-rater reliability measures. Evidence synthesis quality trumps paper quantity in editorial evaluation processes. Reviews that collect studies without critical appraisal or present findings without addressing study quality differences get flagged during screening.

Meta-analysis requirements include proper statistical methodology with heterogeneity assessment, subgroup analysis justification, and sensitivity analysis for study quality differences. Don't attempt meta-analysis without statistical expertise.

Frontiers rejection letters typically include specific scope or methodology feedback. Read carefully for revision guidance rather than immediately seeking alternative journals. Editorial comments often highlight fixable problems that will surface at other journals too.

Don't resubmit to the same section without major changes. Editors remember submissions and authors, so minor revisions after desk rejection usually result in faster secondary rejections. Make substantial scope, framing, or methodology improvements before resubmission attempts.

Use rejection feedback as manuscript improvement guidance that applies beyond Frontiers. If editors consistently flag clinical context issues, address these concerns before submitting elsewhere rather than hoping different editors won't notice identical problems.

Appeal processes exist but rarely succeed unless editors made factual errors about your methodology or scope.

A T cell differentiation study with elegant experimental design got desk rejected because authors focused entirely on molecular mechanisms without mentioning autoimmune diseases, cancer immunotherapy, or vaccine development where Th1/Th2 balance matters clinically. Same data, different framing would've succeeded.

A systematic review of cytokine therapies got submitted to "Immunology" instead of "Immunological Tolerance and Regulation" because authors didn't recognize that therapeutic applications belong in specialized sections. Editorial mismatch caused immediate rejection despite solid methodology.

A COVID-19 immunology paper with strong human data got rejected because authors submitted to "Viral Immunology" during the pandemic when that section was overwhelmed, rather than "Clinical Immunology" where the translational focus would've fit better.

These examples show how editorial fit matters as much as scientific quality.

1. Frontiers in Immunology aims, scope, section descriptions, and author guidance from Frontiers.
2. Frontiers journal guidance on reporting, data availability, and editorial handling expectations.
3. PRISMA guidance relevant to systematic reviews and evidence-synthesis submissions.